The federal government has revealed the outcomes of its latest round of Medicare drug price negotiations, which will lead to lower costs for 15 key medications starting in 2027. One of the most significant reductions comes for Ozempic, Wegovy, and Rybelsus—popular treatments for obesity and Type 2 diabetes—where Medicare will secure a striking 71% discount off their current monthly list prices of approximately $1,000.
These negotiations, which also covered drugs used for conditions such as asthma, breast cancer, and leukemia, resulted in discounts varying from 38% for Austedo, utilized in treating Huntington’s disease, to an impressive 85% for Janumet, another medication for Type 2 diabetes. Health and Human Services Secretary Robert F. Kennedy, Jr. highlighted the government’s commitment to lowering healthcare costs, stating, “As we work to Make America Healthy Again, we will use every tool at our disposal to deliver affordable health care to seniors.”
This new round of negotiations follows the inaugural batch that was launched after the 2022 Inflation Reduction Act, which lifted a long-standing ban on Medicare’s ability to negotiate drug prices. The Centers for Medicare and Medicaid Services (CMS) noted that the newly negotiated prices, if applied in 2024, could have saved Medicare approximately $12 billion. Dr. Benjamin Rome, a health policy researcher, emphasized that the larger savings in this round are attributable not only to the nature of the drugs involved but also to an increased understanding of the negotiation process from previous experiences.
The selection of drugs for negotiation was based on criteria specified in the Inflation Reduction Act, such as the absence of generic or biosimilar alternatives, high Medicare spending, and a presence in the market for several years.
Interestingly, the recent discounts on Ozempic and Wegovy follow a separate agreement made by the Trump administration with Novo Nordisk, the manufacturer of these drugs. That agreement aimed to align U.S. drug prices with those in other developed nations, setting a price of $245 per month for Ozempic and Wegovy. However, the negotiated prices announced this week priced them at $274 a month, leading to questions about the discrepancies between the two agreements. In response, Novo Nordisk acknowledged their eagerness for further clarification from CMS regarding the pricing and coverage terms, stating that their commitment to affordable access remains strong, albeit accompanied by concerns over the Inflation Reduction Act’s potential impact on patients.
Meanwhile, the AARP celebrated the negotiation outcomes, asserting that the lowered prices represent a significant step in the ongoing movement to reduce prescription drug costs. CEO Dr. Myechia Minter-Jordan remarked, “Older Americans across the political spectrum consistently say lower drug prices are a top priority, and these negotiated prices will bring meaningful relief to millions of people on Medicare.”
This development underscores a continued federal effort to enhance healthcare affordability for seniors while signaling broader implications for the pharmaceutical industry in the U.S.
